ESMO 2026

Oncology drug development is under intensifying pressure from complex modalities and fierce competition for sites and patients. ICON helps sponsors respond with strategic insight, scientific leadership and integrated solutions across the full development lifecycle.

Backed by 11,000+ oncology and haematology specialists, ICON has delivered 790+ oncology studies in the past five years, contributing to 57 FDA and EMA‑approved therapies, with faster start‑up and more predictable delivery through connected, research‑ready sites and purpose‑built technology.

Meet our experts at ESMO, Booth #8005 to learn about ICON’s full suite of services to support your Oncology clinical development program.

• Oncology Drug Development Consultancy Services
• Early Phase Oncology
• Feasibility, Site & Patient Recruitment, Site Networks
• Centre for Precision Radiopharmaceuticals
• Centre for Cell & Gene Therapy
• Centre for Pediatric Clinical Development
• Decentralised Clinical Trials, including In-Home Services
• Central, Bioanalytical and Specialty Laboratories
• Cardiac Safety Solutions
• Medical Imaging
• Global Regulatory Consulting
• Real World Data Intelligence and Commercialisation & Outcomes